Spain31.1% survived 18 months with the virus, versus 8.5%.
Median overall survival rose from 8.6 to 10.6 months in metastatic pancreatic cancer.
A virus engineered to make hyaluronidase, an enzyme that breaks down hyaluronan, is infused with chemotherapy.
The overall-survival gain missed significance in the intent-to-treat group, and 22.6% of virus patients had serious events.
The authors say the results warrant a blinded phase 3 trial.
How each outlet framed it
- Nature Medicine leans favorable
- quantifies oncolytic virus efficacy in metastatic pancreatic cancer: 10.8 vs 8.6 month median OS (p=0.055), 7.0 vs 4.6 month PFS
Sources: Nature Medicine